<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989572</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-02101</org_study_id>
    <secondary_id>E4697</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT01989572</nct_id>
    <nct_alias>NCT00005034</nct_alias>
  </id_info>
  <brief_title>Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma</brief_title>
  <official_title>A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With &quot;No Evidence of Disease&quot; After Complete Surgical Resection of &quot;Locally Advanced&quot; and/or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies sargramostim (Granulocyte-macrophage
      colony-stimulating factor, GM-CSF) or vaccine therapy alone to see how well they work
      compared to sargramostim and vaccine therapy together in preventing disease recurrence in
      patients with locally advanced or stage IV melanoma that has been removed by surgery.
      Sargramostim may stimulate the immune system in different ways and stop tumor cells from
      growing. Vaccines made from peptides may help the body build an effective immune response to
      kill tumor cells. It is not yet known whether yeast derived sargramostim and vaccine therapy
      are more effective alone or together in preventing recurrence of melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare overall survival and recurrence-free survival of patients with completely
      resected stage IV melanoma or stage III melanoma with gross extranodal extension, satellites,
      and/or intransit lesions, treated with granulocyte macrophage colony-stimulating factor
      (GM-CSF) (sargramostim) vs. no GM-CSF, or other high risk patients listed in the eligibility
      section.

      SECONDARY OBJECTIVES:

      I. To compare, using a 2 x 2 factorial design, overall survival and recurrence-free survival
      of human leukocyte antigen (HLA)-A2 positive patients treated with peptide vaccination vs. no
      peptide vaccination.

      II. The following descriptive evaluations of survival and recurrence-free survival are
      planned for the HLA-A2 positive patients: (1) GM-CSF plus peptide vaccination vs. peptide
      vaccination alone; (2) GM-CSF plus peptide vaccination vs. GM-CSF alone; (3) GM-CSF plus
      peptide vaccination vs. placebo.

      III. Survival and recurrence-free survival of HLA-A2 positive patients not receiving peptide
      vaccination will be compared to that of HLA-A2 negative patients not receiving peptide
      vaccination.

      IV. To determine the influence of GM-CSF on circulating dendritic cell numbers and
      subpopulations in peripheral blood of patients receiving and not receiving GM-CSF.

      V. To determine, in HLA-A2 positive patients, whether immunization with peptides with or
      without GM-CSF elicits a measurable T-cell response as assessed by enzyme-linked
      immunosorbent spot (ELISPOT) and the major histocompatibility complex (MHC) tetramer assay,
      and to determine the functionality of these cells by intracellular cytokine staining.

      OUTLINE: After patients are screened for HLA-A2 positivity, patients would be categorized
      into two groups: HLA-A2 positive patients and HLA-A2 negative patients. HLA-A2 positive
      patients are randomized to 1 of 4 treatment regimens (Arms I-IV). HLA-A2 negative patients
      are randomized to 1 of 2 treatment arms (Arms V-VI).

      ARM I: Patients receive sargramostim subcutaneously (SC) on days 1-14 and peptide vaccine
      comprising tyrosinase, gp100 antigen, and melanoma antigen recognized by T-cells 1 (MART-1)
      mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG subcutaneously on days
      1 and 15 (course 1) and day 1 (course 2 and subsequent courses).

      ARM II: Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising
      tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant
      or Montanide ISA-51 VG subcutaneously on days 1 and 15 (course 1) and day 1 (course 2 and
      subsequent courses).

      ARM III: Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either
      incomplete Freund's adjuvant or Montanide ISA-51 VG subcutaneously on days 1 and 15 (course
      1) and day 1 (course 2 and subsequent courses).

      ARM IV: Patients receive sargramostim placebo SC on days 1-14 and peptide placebo mixed with
      either incomplete Freund's adjuvant or Montanide ISA-51 VG subcutaneously on days 1 and 15
      (course 1) and day 1 (course 2 and subsequent courses).

      ARM V: Patients receive sargramostim SC on days 1-14.

      ARM VI: Patients receive sargramostim placebo SC on days 1-14.

      In all arms, treatment repeats every 28 days for up to 13 courses in the absence of disease
      progression or unacceptable toxicity.

      In the event of recurrence, patients who undergo complete resection of the recurrence may
      continue treatment for 6 courses or until completion of 1 year of therapy (whichever is
      longer). For patients with recurrence that is not surgically resectable or experiencing
      second recurrence, treatment will be discontinued.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 3 years, and then every 12 months for 15 years.

      PROJECTED ACCRUAL: 800 patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Overall survival is defined as time from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence Free Survival</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Human Leukocyte Antigens-A2 (HLA-A2) Positive Patients</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years,up to year 15</time_frame>
    <description>Overall survival is defined as time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival in HLA-A2 Positive Patients</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Overall Survival Rate</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Overall survival is defined as time from randomization to death from any cause, and 5-year overall survival rate is estimated via Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Recurrence Free Survival Rate</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events, and 5-year overall survival rate is estimated via Kaplan-Meier method. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">815</enrollment>
  <condition>Local Recurrence of Malignant Melanoma of Skin</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I (GM-CSF, peptide vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (GM-CSF placebo, peptide vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (GM-CSF, peptide placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (GM-CSF placebo, peptide placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V (GM-CSF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI (GM-CSF placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (GM-CSF, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm III (GM-CSF, peptide placebo)</arm_group_label>
    <arm_group_label>Arm V (GM-CSF)</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peptide vaccine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (GM-CSF, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm II (GM-CSF placebo, peptide vaccine)</arm_group_label>
    <other_name>TYRP</other_name>
    <other_name>tyrosinase peptide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GM-CSF placebo</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II (GM-CSF placebo, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm IV (GM-CSF placebo, peptide placebo)</arm_group_label>
    <arm_group_label>Arm VI (GM-CSF placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>peptide placebo</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm III (GM-CSF, peptide placebo)</arm_group_label>
    <arm_group_label>Arm IV (GM-CSF placebo, peptide placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have HLA-A2 status known prior to randomization; typing may be obtained
             through a local laboratory facility or through a reference lab utilized by the
             initiating institution; if typing is not available through these means, it may be
             obtained from the University of Pittsburgh

          -  All patients must have disease completely resected with one of the following in order
             to be eligible:

               -  Completely resected disease

               -  Any locoregional recurrence after prior adjuvant interferon or failure on S008

               -  Any local recurrence of disease after adequate surgical excision of the original
                  primary

               -  Mucosal melanoma

               -  Stage IV melanoma (cutaneous, ocular, mucosal, or unknown primary)

          -  The following groups of patients may be entered onto this trial only if they are
             ineligible for S0008 or are, in the opinion of the managing physician, medically unfit
             to receive standard high-dose interferon:

               -  Any clinically evident satellite or in-transit disease

               -  Stage II disease with gross extracapsular extension

               -  Recurrence in a previously resected nodal basin

               -  Four or more involved lymph nodes or matted lymph nodes

               -  Ulcerated primary melanoma and any involved lymph nodes

                    -  NOTE: Patients who are eligible for S0008 will be strongly encouraged to
                       participate in that study in preference to this one

          -  Patients must have been surgically rendered free of disease with negative margins on
             resected specimens; patients rendered free of disease by non-surgical means are not
             eligible

          -  Patients must be randomized within 112 days (16 weeks) of surgical resection; if more
             than one surgical procedure is required to render the patient disease-free, all
             required surgeries must be accomplished within this 16 week time period

          -  Patients must not have received any adjuvant treatment (chemotherapy, biotherapy, or
             limb perfusion) after the resection(s) that make(s) them eligible for this trial; one
             systemic treatment after a prior surgery is allowed, and must have been completed &gt;= 8
             weeks prior to randomization; (when chemotherapy and biotherapy are given together as
             one planned treatment [biochemotherapy], this counts as one regimen); NOTE: Previous
             radiation therapy, including after the resection, is allowed as long as 30 days elapse
             between the radiation and initiation of therapy

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Patients must be able to self-administer or arrange for administration of subcutaneous
             injections

          -  Patients with prior history at any time of any in situ cancer, lobular carcinoma of
             the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark
             I melanoma in situ are eligible; patients who meet this criteria must be disease-free
             at time of randomization

          -  Patients with prior history of basal or squamous skin cancer are eligible; patients
             who meet this criteria must be disease-free at time of randomization

          -  Patients who have had multiple primary melanomas are eligible

          -  Patients with other malignancies are eligible if they have been continuously disease
             free for &gt; 5 years prior to the time of randomization

          -  Patients must not have autoimmune disorders, conditions of immunosuppression or
             treatment with systemic corticosteroids, including oral steroids (i.e., prednisone,
             dexamethasone), continuous use of topical steroid creams or ointments, or any steroid
             containing inhalers; replacement doses of steroids for patients with adrenal
             insufficiency are allowed; patients who discontinue use of these classes of medication
             for at least 2 weeks prior to randomization are eligible if, in the judgment of the
             treating physician, the patient is not likely to require these classes of drugs during
             the study

          -  Women of childbearing potential must not be pregnant (negative beta human chorionic
             gonadotropin [bHCG] within 2 weeks prior to randomization) or breast-feeding

          -  Women of childbearing potential and sexually active males must be counseled to use an
             accepted and effective method of contraception (including abstinence) while on
             treatment and for a period of 18 months after completing or discontinuing treatment

          -  All patients must have brain computed tomography (CT) or magnetic resonance imaging
             (MRI), chest CT or chest x-ray (CXR), and abdominal (liver) CT or MRI within 4 weeks
             prior to randomization; positron emission tomography (PET) scans are also acceptable
             in place of CT, CXR and/or abdominal MRI if obtained within 4 weeks prior to
             randomization; patients with lesions on the lower extremity must also have pelvic
             imaging within this time period; this is also strongly recommended for patients with
             lesions on the lower trunk; PET scans are acceptable

          -  Patients with resection of visceral disease must have imaging of the affected
             area/organ documenting disease-free status within 2 weeks prior to randomization

          -  White blood cells (WBC) &gt;= 3,000/mm³

          -  Platelet count &gt;= 100,000/mm³

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =&lt; 2
             x institutional upper limit (IUL) of normal

          -  Bilirubin =&lt; 2 x IUL of normal

          -  Serum creatinine =&lt; 1.8 mg/dl

          -  Alkaline phosphatase and lactate dehydrogenase (LDH) must be performed within 4 weeks
             prior to randomization; LDH must be normal; patients with abnormal alkaline
             phosphatase which is =&lt; 1.25 times the institutional upper limit of normal who have a
             negative CT or MRI of the liver and negative bone scan or a negative PET scan are
             eligible

          -  Patients with bone pain must have a bone scan within 4 weeks prior to randomization to
             document the absence of tumor

        Exclusion criteria:

          -  Prior treatment with GM-CSF or any peptides used in this protocol

          -  Patients who have other current malignancies are not eligible

          -  Patients have an active infection requiring treatment with parenteral antibiotics

          -  Patients have other significant medical, surgical, or psychiatric conditions or
             require any medication or treatment that may interfere with compliance on any of the
             E4697 treatment regimens

          -  Patients have a diagnosis or evidence of organic brain syndrome or significant
             impairment of basal cognitive function or any psychiatric disorder that might preclude
             participation in the full protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lawson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology, Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2014</results_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced or stage IV melanoma</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>peptide vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was open between December 29, 1999 and October 31, 2006. A total of 815 patients were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (GM-CSF, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
        </group>
        <group group_id="P2">
          <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="P3">
          <title>Arm III (GM-CSF, Peptide Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="P4">
          <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
          <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="P5">
          <title>Arm V (GM-CSF)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
        </group>
        <group group_id="P6">
          <title>Arm VI (GM-CSF Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="107"/>
                <participants group_id="P5" count="190"/>
                <participants group_id="P6" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="186"/>
                <participants group_id="P6" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>error</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>maximum dose reached</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown/not specify</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not start protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients regardless of eligibility and treatment status</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (GM-CSF, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
        </group>
        <group group_id="B2">
          <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="B3">
          <title>Arm III (GM-CSF, Peptide Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="B4">
          <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
          <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="B5">
          <title>Arm V (GM-CSF)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
        </group>
        <group group_id="B6">
          <title>Arm VI (GM-CSF Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="190"/>
            <count group_id="B6" value="189"/>
            <count group_id="B7" value="815"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="27" upper_limit="83"/>
                    <measurement group_id="B2" value="56" lower_limit="22" upper_limit="82"/>
                    <measurement group_id="B3" value="57" lower_limit="23" upper_limit="87"/>
                    <measurement group_id="B4" value="58" lower_limit="23" upper_limit="82"/>
                    <measurement group_id="B5" value="60" lower_limit="19" upper_limit="88"/>
                    <measurement group_id="B6" value="57" lower_limit="19" upper_limit="87"/>
                    <measurement group_id="B7" value="58" lower_limit="19" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>One patient on arm V had missing data for gender. Hence, a total of 189 patients on arm V reported gender.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="77"/>
                    <measurement group_id="B7" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="112"/>
                    <measurement group_id="B7" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as time from randomization to death from any cause.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Patients received GM-CSF in the trial, including patients on arms I, III, V.</description>
          </group>
          <group group_id="O2">
            <title>GM-CSF Placebo</title>
            <description>Patients who did not receive GM-CSF (ie, received GM-CSF placebo) in the trial, including patients on arms II, IV and VI</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as time from randomization to death from any cause.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="53.4" upper_limit="83.5"/>
                    <measurement group_id="O2" value="59.3" lower_limit="44.4" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.528</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on HLA-A2 status, site of metastases and number of metastatic lesions.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Free Survival</title>
        <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Patients received GM-CSF in the trial, including patients on arms I, III, V.</description>
          </group>
          <group group_id="O2">
            <title>GM-CSF Placebo</title>
            <description>Patients who did not receive GM-CSF (ie, received GM-CSF placebo) in the trial, including patients on arms II, IV and VI</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Free Survival</title>
          <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="9.4" upper_limit="14.8"/>
                    <measurement group_id="O2" value="8.8" lower_limit="7.5" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on HLA-A2 status, site of metastases, and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Human Leukocyte Antigens-A2 (HLA-A2) Positive Patients</title>
        <description>Overall survival is defined as time from randomization to death from any cause.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years,up to year 15</time_frame>
        <population>all HLA-A2 positive patients</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Vaccination</title>
            <description>Patients who were HLA-A2 positive and received peptide vaccine in the trial, including 109 patients on arm I and 111 patients on arm II.</description>
          </group>
          <group group_id="O2">
            <title>Peptide Placebo</title>
            <description>Patients who were HLA-A2 positive and received peptide placebo in the trial, including 109 patients on arms III and 107 patients on arm IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Human Leukocyte Antigens-A2 (HLA-A2) Positive Patients</title>
          <description>Overall survival is defined as time from randomization to death from any cause.</description>
          <population>all HLA-A2 positive patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="47.0" upper_limit="92.3"/>
                    <measurement group_id="O2" value="63.3" lower_limit="49.2" upper_limit="105.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on GM-CSF, site of metastases and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Free Survival in HLA-A2 Positive Patients</title>
        <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all HLA-A2 positive patients</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Vaccination</title>
            <description>Patients who were HLA-A2 positive and received peptide vaccine in the trial, including 109 patients on arm I and 111 patients on arm II.</description>
          </group>
          <group group_id="O2">
            <title>Peptide Placebo</title>
            <description>Patients who were HLA-A2 positive and received peptide placebo in the trial, including 109 patients on arms III and 107 patients on arm IV</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Free Survival in HLA-A2 Positive Patients</title>
          <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
          <population>all HLA-A2 positive patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="8.7" upper_limit="20.4"/>
                    <measurement group_id="O2" value="9.8" lower_limit="7.7" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <p_value_desc>stratifying on GM-CSF, site of metastases and number of metastatic lesions</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Overall Survival Rate</title>
        <description>Overall survival is defined as time from randomization to death from any cause, and 5-year overall survival rate is estimated via Kaplan-Meier method.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (GM-CSF, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
          </group>
          <group group_id="O3">
            <title>Arm III (GM-CSF, Peptide Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
            <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O5">
            <title>Arm V (GM-CSF)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (GM-CSF Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Overall Survival Rate</title>
          <description>Overall survival is defined as time from randomization to death from any cause, and 5-year overall survival rate is estimated via Kaplan-Meier method.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="190"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" lower_limit="45.4" upper_limit="64.5"/>
                    <measurement group_id="O2" value="51.9" lower_limit="42.0" upper_limit="61.0"/>
                    <measurement group_id="O3" value="51.1" lower_limit="41.2" upper_limit="60.1"/>
                    <measurement group_id="O4" value="51.6" lower_limit="41.4" upper_limit="60.9"/>
                    <measurement group_id="O5" value="51.2" lower_limit="43.8" upper_limit="58.2"/>
                    <measurement group_id="O6" value="46.7" lower_limit="39.3" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparison in patients with positive HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparison in patients with negative HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Recurrence Free Survival Rate</title>
        <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events, and 5-year overall survival rate is estimated via Kaplan-Meier method. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (GM-CSF, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
          </group>
          <group group_id="O3">
            <title>Arm III (GM-CSF, Peptide Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
            <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O5">
            <title>Arm V (GM-CSF)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (GM-CSF Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Recurrence Free Survival Rate</title>
          <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events, and 5-year overall survival rate is estimated via Kaplan-Meier method. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="190"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="23.6" upper_limit="41.5"/>
                    <measurement group_id="O2" value="33.2" lower_limit="24.4" upper_limit="42.2"/>
                    <measurement group_id="O3" value="31.3" lower_limit="22.8" upper_limit="40.2"/>
                    <measurement group_id="O4" value="28.0" lower_limit="19.7" upper_limit="36.9"/>
                    <measurement group_id="O5" value="30.6" lower_limit="24.1" upper_limit="37.3"/>
                    <measurement group_id="O6" value="22.9" lower_limit="17.1" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparison in patients with positive HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparisons in patients with negative HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every cycle (1 cycle=28 days) for cycles 1, 2, 3, and 4; after cycle 4, assessed every 3 months (at the completion of cycles 7, 10, 13) while on treatment and for 30 days after the end of treatment</time_frame>
      <desc>After off treatment, if the patient experienced any clinical problems possibly related to the protocol treatment, the clinical problems were also reported per the standard ECOG follow-up schedule: every 3 months if patient is &lt;2 years from study entry, every 6 months if patient is 2-5 years from study entry, and every 12 months if &gt;5 years.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (GM-CSF, Peptide Vaccine)</title>
          <description>Arm I (GM-CSF, peptide vaccine) Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC peptide vaccine: Given SC</description>
        </group>
        <group group_id="E2">
          <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
          <description>Arm II (GM-CSF placebo, peptide vaccine) Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="E3">
          <title>Arm III (GM-CSF, Peptide Placebo)</title>
          <description>Arm III (GM-CSF, peptide placebo) Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC peptide placebo: Given SC</description>
        </group>
        <group group_id="E4">
          <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
          <description>Arm IV (GM-CSF placebo, peptide placebo) Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC peptide placebo: Given SC</description>
        </group>
        <group group_id="E5">
          <title>Arm V (GM-CSF)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
        </group>
        <group group_id="E6">
          <title>Arm VI (GM-CSF Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <description>infection with grade 3 or 4 neutropenia</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <description>infection with unknown ANC</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <description>infection w/o neutropenia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue di</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specif</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="180" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="143" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="66" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>General disorders and administration sit</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="147" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders -</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

